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ABSTRACT
Objectives Atrial fibrillation (AF) is a heart condition 
associated with a fivefold increased risk of stroke. The 
condition can be detected in primary care and treatment 
can greatly reduce the risk of stroke. In recent years, a 
number of policy initiatives have tried to improve diagnosis 
and treatment of AF, including local National Health Service 
schemes and the Quality and Outcomes Framework. We 
aimed to examine trends in the incidence of recorded AF in 
primary care records from English practices between 2004 
and 2018.
Design Longitudinal cohort study.
Setting English primary care electronic health records 
linked to Index of Multiple Deprivation data.
Participants Cohort of 3.5 million patients over 40 years 
old registered in general practices in England, contributing 
22 million person- years of observation between 2004 and 
2018.
Primary and secondary outcome measures Incident 
AF was identified through newly recorded AF codes in the 
patients’ records. Yearly incidence rates were stratified by 
gender, age group and a measure of deprivation.
Results Incidence rates were stable before 2010 and then 
rose and peaked in 2015 at 5.07 (95% CI 4.94 to 5.20) 
cases per 1000 person- years. Incidence was higher in 
males (4.95 (95% CI 4.91 to 4.99) cases per 1000 person- 
years vs 4.12 (95% CI 4.08 to 4.16) in females) and rises 
markedly with age (0.58 (95% CI 0.56 to 0.59) cases per 
1000 person- years in 40–54 years old vs 21.7 (95% CI 
21.4 to 22.0) cases in over 85s). The increase in incidence 
over time was observed mainly in people over the age of 
75, particularly men. There was no evidence that temporal 
trends in incidence were associated with deprivation.
Conclusions Changes in clinical practice and policy 
initiatives since 2004 have been associated with increased 
rates of diagnosis of AF up until 2015, but rates declined 
from 2015 to 2018.
INTRODUCTION
Atrial fibrillation (AF) is a cardiac arrhythmia 
that is associated with a fivefold increase in 
risk of stroke.1 The risk of stroke associated 
with AF can be greatly reduced by use of 
anticoagulants. AF is associated with 1 in 5 
stroke cases2 and is considered to be underdi-
agnosed3 and undertreated.4 Consequently, 
AF has been the target of a number of policy 
initiatives in recent years aimed at both treat-
ment and diagnosis. In the UK, it has been 
part of the Quality and Outcomes Framework 
(QOF) since 2006,5 the pay- for- performance 
scheme that incentivises the recording and 
appropriate management of chronic condi-
tions. Since 2008, there have been several 
local National Health Service (NHS) schemes 
to incentivise detection and management of 
AF including the Guidance on Risk Assess-
ment and Stroke Prevention for Atrial Fibril-
lation electronic tool6 and opportunistic 
screening by manual pulse checks.5 It is the 
subject of a national programme coordinated 
by the Academic Health Sciences Network.2 
The need for better detection is highlighted 
in the NHS Long Term Plan (2019).7 There 
is evidence from both UK and international 
studies of a rise in the age- specific incidence 
of AF,8 9 including two using UK electronic 
primary care records.10 11 However, these have 
not used data beyond 2011. Given that policy 
initiatives continue to focus on AF, our aim 
was to describe temporal trends in recorded 
AF in a nationally representative sample of 
primary care records up until 2018.
Strengths and limitations of this study
 ► Our population- based sample covered 3.5 million 
patients at risk over a period of 15 years.
 ► The data from the Clinical Practice Research 
Datalink used in this study have been shown to be 
representative of the UK population and to be of high 
quality for the recording of diagnoses, particularly 
for chronic conditions.
 ► Atrial fibrillation (AF) has been part of the Quality and 
Outcomes Framework since 2007 and is likely to be 
well recorded in primary care records.
 ► A limitation is that these reported incidence rates 
exclude patients with undiagnosed AF, or that do not 
have their diagnosis recorded in their primary care 
records.




We used data from the Clinical Practice Research Data-
link (CPRD) GOLD, a database of electronic primary care 
records in the UK, based on patients attending general 
practices which use the Vision computer system. CPRD 
has been shown to be nationally representative of the UK 
population12 and data quality is monitored at the practice 
and patient level. In 2013, it contained the medical records 
of over 11 million patients, with 4.4 active (currently 
registered) patients corresponding to about 7% of the 
UK population.12 During the study period (2004–2018) 
the number of UK practices contributing data to CPRD 
varied from 680 to 367 (online supplemental appendix 1) 
due to a reduction of practices using the Vision computer 
system. The data collected from CPRD include all clin-
ical codes for medical diagnoses entered at consultations, 
referrals, tests and all prescriptions issued at the practice.
Study cohort and disease definition
The study population included patients from English 
practices aged over 40 years between 1 January 2004 and 
31 December 2018. Recorded AF was identified using a 
list of eight Read codes (online supplemental appendix 
2). This list was developed as part of a project on the 
epidemiology of multimorbidity13 14 and was based orig-
inally on the QOF business rules. We used the October 
2019 data release of CPRD GOLD.
Data analysis
AF incidence was estimated as the number of new AF 
cases during each year, divided by the eligible follow- up 
(person- time at risk). Eligible follow- up for all patients 
(with and without AF) was calculated using the CPRD 
denominator files, which contain basic information about 
each patient and practice. Start of follow- up was calcu-
lated as the latest of 1 year after the patient first regis-
tered at the practice, the practice up to standard date (an 
internal measure of CPRD data quality based on consis-
tency of data provided to CPRD by the practice12) and 1 
January 2004 (study start). The end of follow- up was the 
earliest of the last date the patient was registered at the 
practice, date of death, the last date the practice contrib-
uted data to CPRD, or 31 December 2018. We restricted 
follow- up to start 1 year after registration at the practice 
to avoid capturing historical diagnosis.
People with a new AF medical code recorded for the 
first time during the eligible follow- up period were iden-
tified as incident cases and counted towards the numer-
ator. Those people with any AF code identified before 
the start of eligible follow- up were considered prevalent 
cases and were excluded. Cases registered after the 
end of eligible follow- up were also excluded from the 
numerator, except for a few cases that occurred within 
3 months of death or transfer out date. We decided 
to include these as they probably relate to events that 
occurred within eligible follow- up but that were regis-
tered later. AF cases that occurred within or after 
eligible follow- up contribute time at risk to the denom-
inator until their date of diagnosis or end of follow- up, 
whichever is first.
Incidence rates are calculated as the number of new 
cases of AF in our eligible population and study period 
(numerator) divided by the total person- time at risk 
(denominator). The denominator was the sum of the 
person- time at risk for all eligible patients (cases and 
non- cases).
The patients’ sex and year of birth were available from 
CPRD. We assumed the patients’ date of birth to be the 
midyear (ie, 30 June) of year of birth. Patients’ age was 
grouped into five categories: 40–54, 55–64, 65–74, 75–84 
and ≥85 years old.
Stratified incidence rates by calendar year and socio-
demographic characteristics were calculated through the 
use of a Lexis expansion.15 Each patient- time at risk was 
split into multiple time periods according to their age 
group and calendar years. Time at risk is then added up 
within each stratum, a combination of calendar year by 
age group by gender (eg, women aged 65–74 in 2016). 
The incidence rate corresponds to the number of AF cases 
divided by the total person- time at risk in that stratum. P 
values for the crude effects were derived from unadjusted 
Poisson models; p values for the effect of age and gender 
were calculated using a gender- stratified model and a 
model with the two- way interaction.
In order to take into account possible changes over 
time in the age composition of the sample, we have addi-
tionally estimated modelled incidence rates. We used a 
Poisson regression approach using the number of events 
in each stratum as the main outcome and including the 
logarithm of follow- up time as an offset. The model for 
all patients included the main effect variables year, age 
group and sex, and their two- way and three- way inter-
actions. Year and sex were always treated as categorical 
variables but age group was treated as a continuous vari-
able for the interaction terms only in order to maximise 
power. Each model was used to predict the incidence rate 
for each year adjusting for the case mix characteristics of 
the whole sample (known as marginal standardisation).16
Incidence by deprivation was calculated using a CPRD 
patient denominator file stratified by the patient- level 
2010 English Index of Multiple Deprivation (IMD) quin-
tiles and the linked patient- level IMD quintiles for the 
patients with newly registered AF. For this data linkage, 
data are only available until the end of 2016. To model 
the effect of deprivation we used the same model as the 
main analysis but adding in a categorical main effect for 
deprivation quintile and an interaction between year and 
deprivation quintile (treated as a linear term).
Data manipulation and analyses were performed in 
Stata V.15.1 (StataCorp). We report 95% CIs calculated as 
exact Poisson CIs.
Patient and public involvement
Patients and the public were not involved in this study.
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RESULTS
In a study population of nearly 3.5 million patients 
contributing a total of 22 million person- years of obser-
vation, there were 99 836 newly registered AF cases (see 
patient selection flow chart in online supplemental 
appendix 3) with a mean age at diagnosis of 74.6 years 
(see table 1). Over 55% of new diagnoses were in people 
over the age of 75. The overall incidence is 4.52 cases 
per 1000 patient- years in people aged over 40 years, and 
11.6 per 1000 patient- years in people aged 65 years and 
older. The incidence rises by age, up to 21.7 per 1000 
in people aged 85 or over, and is higher in men than 
women, 4.95 vs 4.12 per 1000 person- years (table 2). 
There was evidence of significant variation associated 
with the effects of age and gender (p<0.001 for both, 
table 2). We also noted that incidence increases with age 
differently for men and women (p<0.001, table 2 and 
figure 1).
Incidence of AF was relatively stable between 2004 and 
2010, between 4.2 and 4.5 cases per 1000 person- years, 
then increased up until 2015, when incidence peaked 
at 5.1 cases per 1000 person- years, before falling back 
to 4.6 cases per 1000 person- years by 2018 (see figure 1 
and online supplemental appendix 4). There was strong 
evidence of variation between years (p<0.001). This 
post-2015 decline occurred primarily in women. The 
age- specific trends show that the increase between 2010 
and 2015 occurred largely in people aged 75 and over, 
and more so in men (figure 2 and online supplemental 
appendix 5).
Incidence of AF was higher in the most deprived quin-
tile of IMD than in the least deprived quintile (p=0.002 
for the effect of deprivation; online supplemental appen-
dices 6 and 7). There was no evidence of differences in 




We observed stable AF incidence from 2004 to 2010, 
increased incidence from 2010 to 2015 and then falling 
incidence from 2016 to 2018. The rise in incidence was 
primarily in people aged 75 and over and most marked 
in men. The decline from 2016 to 2018 reflected falling 
incidence in women rather than men.
Strengths and limitations
A strength of this study was the use of a large sample that 
is representative of the English population, permitting a 
detailed description of current practice. It is important to 
note that the focus of this study was recorded (or clinically 
detected) AF, and thus patients with undiagnosed, or 
who are diagnosed but not recorded will not be included. 
Table 1 Characteristics of patients with newly diagnosed 
AF in the period 2004–2018
n (%)
All patients 99 836
Gender
  Men 52 823 (52.9)
  Women 47 013 (47.1)
Age, mean (SD) 74.6 (11.2)
Age group
  40–54 5597 (5.6)
  55–64 12 598 (12.6)
  65–74 26 308 (26.4)
  75–84 36 215 (36.3)
  85+ 19 118 (19.1)
AF, atrial fibrillation.
Table 2 Observed incidence rates (per 1000 person- years) 
for recorded AF during the period 2004–2018, stratified by 
age and gender
Incidence 
rate 95% CI P value*
All patients 4.52 4.49 to 4.55
Gender <0.001
  Female 4.12 4.08 to 4.16
  Male 4.95 4.91 to 4.99
Age group <0.001
  40–54 0.58 0.56 to 0.59
  55–64 2.36 2.32 to 2.40
  65–74 6.84 6.76 to 6.93
  75–84 15.5 15.3 to 15.7
  85+ 21.7 21.4 to 22.0
Gender and age 
group
<0.001
  Women <0.001
  40–54 0.32 0.30 to 0.34
  55–64 1.52 1.48 to 1.57
  65–74 5.24 5.14 to 5.34
  75–84 13.7 13.5 to 13.9
  85+ 20.3 20.0 to 20.7
  Men <0.001
  40–54 0.83 0.80 to 0.85
  55–64 3.20 3.14 to 3.27
  65–74 8.61 8.48 to 8.75
  75–84 18.0 17.7 to 18.3
  85+ 24.8 24.2 to 25.3
*The p values presented in this table come from unadjusted 
tests of whether there is variation by age and sex (overall, top 
two sets of rows) and variation by age, stratified by sex (below, 
bottom two sets of rows). The interaction p value, however, has 
a slightly different interpretation and presents a measure of the 
strength of evidence of whether the effect of age is different for 
men and women (middle row).
AF, atrial fibrillation.
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However, diagnosis and inclusion in population registers 
is essential to ensure adequate care and stroke preven-
tion, and the focus of this study was to describe the inci-
dence of clinically detected AF. Our modelled incidence 
rates remove the effect that possible changes in the popu-
lation case mix over time could have on observed rates. 
However, changes in the number of practices using the 
Vision computer system in recent years could be contrib-
uting to the levelling off in incidence rates observed after 
2015.17
Comparison with existing literature
Incidence rates for AF can vary considerably between 
different studies, most likely due to different source 
populations, case definitions and study periods. The rates 
reported in this study are similar to those described in 
other European cohorts from Iceland18 and the Nether-
lands,19 but lower than one from Germany.20 In general, 
incidence rates reported from American cohorts21–23 are 
higher than those from Europe, including our own study.
In the UK population, we found two studies that 
looked at incidence of AF over time.10 11 Scowcroft and 
Cowie calculated incidence rates between 2000 and 2012 
while Lane et al report incidence rates between 1998 and 
2010. Both studies use data from CPRD and also report 
increases in incidence (Scowcroft and Cowie from 2009 
onwards and Lane et al between the periods 1998–2001 
and 2002–2006). We found higher incidence rates than 
those reported by Lane et al and Scowcroft and Cowie. 
Whereas we restricted our analysis to people aged 40 
years and over, they both reported incidence in people 
aged 18 years and over. However, even when looking 
at comparable age groups, our rates were higher. For 
example, Lane et al reported an incidence rate of 3.26 
per 1000 people aged 65–74 between 2007 and 2010, 
whereas the observed incidence rate in our study in this 
age group was 6.84 per 1000. This is likely to reflect analyt-
ical differences in how the denominator population was 
defined. In our study, we derived both the numerator and 
the denominator by first defining the eligible follow- up 
period for all patients and then identifying which AF 
cases fell in this eligibility period. In the other two UK 
studies, these figures appear to have been derived sepa-
rately, with stricter criteria applied to the cases (eg, Scow-
croft and Cowie impose a minimum of 1 year both before 
and after diagnosis) than to the denominator, resulting 
in lower rates, though the observed temporal trends will 
not have been affected. We believe our estimates are truer 
reflections of the incidence of AF. A recent meta- analysis 
of AF screening studies in a general population estimated 
a detection rate of 1.44% in patients aged 65 and over.24 
This is slightly higher than our estimate of 1.16 cases 
Figure 1 Modelled incidence of recorded atrial fibrillation 
over time.
Figure 2 Modelled incidence of recorded atrial fibrillation 
over time stratified by age group and gender.
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per 100 person- years in the comparable age group (see 
online supplemental appendix 8), which is what would be 
expected given that these were screening studies, whereas 
ours would have identified only those picked up from 
active case finding.3 Further corroborative evidence that 
our incidence rates are more likely to be correct comes 
from the Framingham study, which reported incidence 
rates of 13.4 per 1000 in men over the age of 50, and 
8.6 per 1000 in women. The higher rates in Framingham 
study, despite the slightly younger age group, reflect the 
multiple sources of ascertainment that were used to iden-
tify AF. Detection rates from routine practice will be lower 
than those.
Ours is the first study to demonstrate a decline in the 
incidence of recorded AF between 2015 and 2018 in the 
UK, after taking account of changes over time in age 
composition of the population. Given that epidemiolog-
ical studies such as Framingham have reported increases 
rather than decreases in AF incidence,9 this is likely to 
reflect a change in ascertainment in recent years.
Implications for research, policy and practice
Our results suggest that initiatives in policy and clinical 
practice since 2004 have been associated with increased 
rates of diagnosis of AF (table 3). Although the increase 
in incidence seen in over 85 year- olds may be explained 
in part by the increased mean age of this group over 
time, it is also plausible that initiatives to encourage pulse 
palpation in over 65s,5 or improved perceived tolerability 
of newer anticoagulants25 have influenced clinicians 
to increase efforts to diagnose older patients. It is also 
notable that increases in AF diagnosis do not appear to 
have come at the expense of the widening social inequality 
that has been of particular concern in conditions such 
as cancer.26 The small decline in AF incidence since 
2015 may reflect reducing policy emphasis or a decline 
in the primary care workforce available to detect AF.27 
The decline in incidence may also reflect that ‘catch up’ 
diagnoses were made in the years prior to 2015, boosting 
apparent incidence during that period. Given the emer-
gence of new technologies which allow self- diagnosis of 
AF, it is likely that the incidence of diagnosis of AF will rise 
again in the future.28 Indeed, data from studies that have 
used implantable loop recorders to detect AF suggest that 
there may be substantial proportions of people with short 
episodes of undiagnosed AF.29
It is important to continue to monitor trends in AF inci-
dence to assess impact of new technologies and initiatives. 
Our finding that incidence of AF in the under 65 age 
group remained low and did not change during the study 
period suggests first that there has been no substantive 
shift in the clinical presentation of this group to primary 
care that has led to changes in AF incidence in this popu-
lation. Policy initiatives such as incentives for opportu-
nistic screening have not focused on younger people with 
AF; our study would tend to support this approach as the 
numbers of people identified would be likely to be very 
low.
Our research has also highlighted the methodological 
point that researchers should ensure they use the correct 
denominators for studies of incidence in primary care 
database analyses as small changes in approaches can 
lead to substantial errors in published rates, with poten-
tially large implications for policy decisions based on 
these estimates. We would recommend that policymakers 
base future modelling decisions and analyses on the rates 
presented in this, rather than previous studies.
CONCLUSION
The incidence of diagnosed AF increased in the UK 
between 2004 and 2015, with the greatest increase among 
patients aged over 85, but with a small decline between 
2015 and 2018. Trials of AF screening that are powered 
to detect impact on stroke rates will provide evidence on 
the extent to which efforts should be made to reverse this 
decline.30
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